COMPANY

Virogenomics Biodevelopment, Inc.

HQ: Tigard, OR source · virogenomics.com ↗ · West Coast

Location: Tigard, OR · source · Oct 15, 2026

Profile checked Oct 10, 2026

29NIH grants

Funding and NIH signals

NIH award NIH awarded $400K (STTR Phase I 1R41DA064189-01, new, notice May 27, 2026); 2 NIH awards totaling $3.7M in the last 12 months. NIH RePORTER 1R41DA064189-01 (May 27, 2026)
Evidence (2 events)
- May 27, 2026 · NIH RePORTER 1R41DA064189-01
  Organization: VIROGENOMICS BIODEVELOPMENT, INC.; City/State: Tigard, OR; Project number: 1R41DA064189-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-27; FY total cost (award amount): 399889; Administering IC: National Institute on Drug Abuse; Project title: Treatment of CNS damage from non-disordered drug use with DRhQ, a novel regulator of CD74 signaling; Organization type: Domestic For-Profits
- Apr 24, 2026 · NIH RePORTER 5UG3DA061709-02
  Organization: VIROGENOMICS BIODEVELOPMENT, INC.; City/State: Tigard, OR; Project number: 5UG3DA061709-02; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-04-24; FY total cost (award amount): 3300978; Administering IC: National Institute on Drug Abuse; Project title: IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

May 27, 2026 Grant Government grant — STTR: $399,889 (annual award, as published), announced May 27, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
Apr 24, 2026 Grant Government grant — NIH UG3: $3.3M (annual award, as published), announced Apr 24, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
May 12, 2025 Grant Government grant — NIH UG3: $3.29M (annual award, as published), announced May 12, 2025. Agency: NIH/NIDA. Source: government award database. source ↗

Funding

Last 2 years.

May 27, 2026 Government grant — STTR: $399,889 (annual award, as published), announced May 27, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
Apr 24, 2026 Government grant — NIH UG3: $3.3M (annual award, as published), announced Apr 24, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
May 12, 2025 Government grant — NIH UG3: $3.29M (annual award, as published), announced May 12, 2025. Agency: NIH/NIDA. Source: government award database. source ↗

NIH awards 29

Annual award amounts. Total $10.0M.

Jun 6, 2024 NIH award 1R41DA059296-01A1 FY2024: $405,334 awarded for that fiscal year; activity R41 (STTR); PI SHIRLEY, RENEE LYNN; recipient as written: VIROGENOMICS BIODEVELOPMENT, INC., Tigard, OR. Immunotherapeutic Targeting source ↗
Mar 17, 2022 NIH award 5R44AI122574-06 FY2022: $996,486 awarded for that fiscal year; activity R44 (SBIR); PI SHIRLEY, RENEE LYNN; recipient as written: VIROGENOMICS BIODEVELOPMENT, INC., Tigard, OR. Development of DRα1-MOG-35-55 source ↗
Mar 18, 2021 NIH award 5R44AI122574-05 FY2021: $996,926 awarded for that fiscal year; activity R44 (SBIR); PI KING, JEFFREY S; recipient as written: VIROGENOMICS BIODEVELOPMENT, INC., Tigard, OR. Development of DRα1-MOG-35-55 for source ↗
Apr 16, 2020 NIH award 2R44AI122574-04A1 FY2020: $998,210 awarded for that fiscal year; activity R44 (SBIR); PI KING, JEFFREY S; recipient as written: VIROGENOMICS BIODEVELOPMENT, INC., Tigard, OR. Development of DRα1-MOG-35-55 f source ↗
Sep 25, 2019 NIH award 1R43HL147757-01 FY2019: $268,643 awarded for that fiscal year; activity R43 (SBIR); PI KING, JEFFREY S; recipient as written: VIROGENOMICS BIODEVELOPMENT, INC., Tigard, OR. Developing novel fibrillin biomar source ↗
Mar 7, 2019 NIH award 1R41DA047865-01A1 FY2019: $299,560 awarded for that fiscal year; activity R41 (STTR); PI LOFTIS, JENNIFER M; recipient as written: VIROGENOMICS BIODEVELOPMENT, INC., Tigard, OR. DRα1-MOG as a Next-Generatio source ↗
May 31, 2018 NIH award 5R42AI122574-03 FY2018: $747,347 awarded for that fiscal year; activity R42 (STTR); PI VANDENBARK, ARTHUR A.; recipient as written: VIROGENOMICS BIODEVELOPMENT, INC., Tigard, OR. Development of DRα1-MOG-35- source ↗
Jul 18, 2017 NIH award 1R41NS103644-01 FY2017: $299,186 awarded for that fiscal year; activity R41 (STTR); PI ALKAYED, NABIL J; recipient as written: VIROGENOMICS BIODEVELOPMENT, INC., Tigard, OR. DRα1-MOG: A Novel Immunomodulato source ↗
Jul 17, 2017 NIH award 2R42AI122574-02 FY2017: $702,706 awarded for that fiscal year; activity R42 (STTR); PI VANDENBARK, ARTHUR A.; recipient as written: VIROGENOMICS BIODEVELOPMENT, INC., Tigard, OR. Development of DRα1-MOG-35- source ↗
Sep 21, 2016 NIH award 1R43CA203681-01A1 FY2016: $299,931 awarded for that fiscal year; activity R43 (SBIR); PI KING, JEFFREY S; recipient as written: VIROGENOMICS BIODEVELOPMENT, INC., Tigard, OR. Sensitive Single Cell PhosphoCo source ↗
Feb 1, 2016 NIH award 1R41AI122574-01 FY2016: $224,796 awarded for that fiscal year; activity R41 (STTR); PI VANDENBARK, ARTHUR A.; recipient as written: VIROGENOMICS BIODEVELOPMENT, INC., Tigard, OR. Development of DRα1-MOG-35- source ↗
Jun 17, 2015 NIH award 1R41DA039632-01 FY2015: $224,886 awarded for that fiscal year; activity R41 (STTR); PI LOFTIS, JENNIFER M; recipient as written: VIROGENOMICS BIODEVELOPMENT, INC., Tigard, OR. Preclinical and neuroimmunolog source ↗
Aug 9, 2007 NIH award 1R41AI072906-01A1 FY2007: $289,487 awarded for that fiscal year; activity R41 (STTR); PI HEFFRON, FRED L; recipient as written: VIROGENOMICS, INC., TIGARD, OR. Genetically Defined Attenuated Living Vaccine source ↗
Jul 31, 2007 NIH award 5R42DK068881-03 FY2007: $376,680 awarded for that fiscal year; activity R42 (STTR); PI BURROWS, GREGORY GEORGE; recipient as written: VIROGENOMICS, INC., TIGARD, OR. HLA-DQ-derived RTLs for Treatment of Cel source ↗
Aug 31, 2006 NIH award 1R41EY017781-01 FY2006: $100,726 awarded for that fiscal year; activity R41 (STTR); PI ADAMUS, GRAZYNA; recipient as written: VIROGENOMICS, INC., TIGARD, OR. Recombinant T-cell Receptor Ligands for Treatmen source ↗
Aug 21, 2006 NIH award 5R42NS046827-03 FY2006: $376,909 awarded for that fiscal year; activity R42 (STTR); PI STENZEL-POORE, MARY P; recipient as written: VIROGENOMICS, INC., TIGARD, OR. Osteopontin, a Novel Neuroprotectant in Br source ↗
Aug 21, 2006 NIH award 2R42DK068881-02 FY2006: $374,744 awarded for that fiscal year; activity R42 (STTR); PI BURROWS, GREGORY GEORGE; recipient as written: VIROGENOMICS, INC., TIGARD, OR. HLA-DQ-derived RTLs for Treatment of Cel source ↗
Sep 30, 2005 NIH award 1R41MD001833-01A1 FY2005: $100,548 awarded for that fiscal year; activity R41 (STTR); PI HUAN, JIANYA; recipient as written: VIROGENOMICS, INC., TIGARD, OR. HLA-DR4-derived RTLs for Treating Rheumatoid Arth source ↗
Sep 20, 2005 NIH award 2R42NS046827-02 FY2005: $374,807 awarded for that fiscal year; activity R42 (STTR); PI STENZEL-POORE, MARY P; recipient as written: VIROGENOMICS, INC., TIGARD, OR. Osteopontin, a Novel Neuroprotectant in Br source ↗
Aug 18, 2005 NIH award 5R42NS046877-03 FY2005: $359,127 awarded for that fiscal year; activity R42 (STTR); PI VANDENBARK, ARTHUR A.; recipient as written: VIROGENOMICS, INC., TIGARD, OR. Development of a T cell specific multiple source ↗
Sep 29, 2004 NIH award 1R41DK068881-01 FY2004: $102,839 awarded for that fiscal year; activity R41 (STTR); PI BURROWS, GREGORY GEORGE; recipient as written: VIROGENOMICS, INC., TIGARD, OR. HLA-DQ-derived RTLs for Treatment of Cel source ↗
Sep 24, 2004 NIH award 2R42NS046877-02 FY2004: $361,013 awarded for that fiscal year; activity R42 (STTR); PI VANDENBARK, ARTHUR A.; recipient as written: VIROGENOMICS, INC., TIGARD, OR. Development of a T cell specific multiple source ↗
Sep 22, 2003 NIH award 1R41NS046877-01 FY2003: $99,808 awarded for that fiscal year; activity R41 (STTR); PI VANDENBARK, ARTHUR A.; recipient as written: VIROGENOMICS, INC., TIGARD, OR. Development of a T cell specific multiple s source ↗
Sep 5, 2003 NIH award 1R41NS046827-01 FY2003: $99,703 awarded for that fiscal year; activity R41 (STTR); PI STENZEL-POORE, MARY P; recipient as written: VIROGENOMICS, INC., TIGARD, OR. Osteopontin, a novel neuroprotectant in bra source ↗
2003 NIH award 1R41AI055218-01 FY2003: $99,808 awarded for that fiscal year; activity R41 (STTR); PI MOSES, ASHLEE V; recipient as written: VIROGENOMICS, INC., TIGARD, OR. Identifying cellular genes as anti-HIV drug targe source ↗
Sep 18, 2002 NIH award 1R43HL071360-01 FY2002: $96,845 awarded for that fiscal year; activity R43 (SBIR); PI HICKS, JAMES B; recipient as written: VIROGENOMICS, INC., TIGARD, OR. Treatment of HCMV in transplant vascular scelrosis source ↗
Jun 1, 2002 NIH award 1R43AI050999-01 FY2002: $98,329 awarded for that fiscal year; activity R43 (SBIR); PI HICKS, JAMES B; recipient as written: VIROGENOMICS, INC., TIGARD, OR. Improved cell culture systems for Hepatitis C viru source ↗
Feb 13, 2002 NIH award 1R43AI051066-01 FY2002: $96,105 awarded for that fiscal year; activity R43 (SBIR); PI HICKS, JAMES B; recipient as written: VIROGENOMICS, INC., TIGARD, OR. A method for treating HCMV in vascular disease source ↗
Jul 30, 1998 NIH award 1R43MH059728-01 FY1998: $98,005 awarded for that fiscal year; activity R43 (SBIR); PI HICKS, JAMES B; recipient as written: VIROGENOMICS, INC., TIGARD, OR. DYNAMIC MODEL FOR THE HIV BLOOD BRAIN BARRIER source ↗